Global Meloxicam Market, By Diseases (Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Others), Drug Type (Generic, Branded), Population Type (Adult, Children), Dosage (Oral, Parenteral, transdermal, Others), Dose Strength (7.5mg, 15mg, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa), Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Meloxicam Market
Global Meloxicam market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a healthy CAGR 5.00% in the above-mentioned research forecast period. Rising osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis are the factors responsible for the growth of this market.
However, rising preference of NSAIDs over other pain killers such as opioids also boost up the market growth. Moreover, rising prevalence of chronic inflammatory and pain diseases also boost up the market growth. But, market competition among the players and severe side effects such as ulcers, dizziness and others may hamper the global Meloxicam market.
Meloxicam is a non-steroidal anti-inflammatory drug which is used to relieve the chronic inflammation and pain including pain caused by osteoarthritis, rheumatoid arthritis and musculoskeletal conditions. Meloxicam have longer half-life as compared to the other NSAIDs. It is a preferential COX-2 inhibitor, reportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy. It is estimated that in 2018, 22.6 million of prescriptions in the United States.
Meloxicam inhibits PG synthetase (such as COX-1 & COX-2) enzyme which leads to a decreased synthesis of prostaglandins. Meloxicam preferentially inhibits COX-2, but also exerts some activity against COX-1, causing gastrointestinal irritation.
This Meloxicam market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Meloxicam Market Scope and Market Size
The Meloxicam market is segmented on the basis of disease, drug type, population type, dosage, dose strength, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of diseases, the Meloxicam market is segmented into osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis and others.
- On the basis of drug type, the Meloxicam market is segmented into branded and generics. Branded drugs further segmented into Mobic, Muvera and others.
- On the basis of population type, the Meloxicam market is segmented into adults and children.
- On the basis of dosage, the Meloxicam market is segmented into oral, parenteral, transdermal and others.
- On the basis of dose strength, the Meloxicam market is segmented into 7.5mg, 15mg and others.
- On the basis of end-users, the Meloxicam market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, Meloxicam market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Meloxicam Market Country Level Analysis
Meloxicam market is analysed and market size information is provided by country, disease, drug type, population type, dosage, dose strength, end-users and distribution channel as referenced above.
The countries covered in the Meloxicam market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the presence of rising population with arthritis & other chronic pain diseases, high healthcare expenditure and research & development. Europe accounts the second largest market share due to presence of refined medical facilities. Asia-Pacific is expected to account for the largest market share over coming years for the Meloxicam market due to increased advancement in the technology as well as growing healthcare expenditure and rising awareness program.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Meloxicam market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Meloxicam Market Share Analysis
Meloxicam market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Meloxicam market.
The major players covered in the Meloxicam market are Taj Pharmaceutical Limited., Wellona Pharma, Trumac Healthcare, Healthy Life Pharma Private Limited., EPICON LIFESCIENCES LLP, Boehringer Ingelheim GmbH., Baudax Bio, Viatris Inc., Avanstra Inc., PD-Rx Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited., Teva Pharmaceutical Industries limited, Dr Reddy's Laboratories, Lupin, Apotex Corporation, among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-